“Assay”的搜索结果，显示 131-140 项，共有 5543 项

1. 放射科- 临床试验- 妙佑医疗国际

   ... assay. This will be done by comparing pre-and-post MRI hs-cTnT levels in these patients. Improvements In Dynamic Contrast-Enhanced MR Angiography And ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood. A Bio-bank for Patients ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR). Rochester, Minn. The purpose of this ...

5. 血液科- 临床试验- 妙佑医疗国际

   ... assay. A database of paired clinical and sequencing data will also be established for future research. Inotuzumab Ozogamicin and Frontline Chemotherapy in ...

6. 血液科- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to compare whether minimal residual disease (MRD) flow cytometric assay is not affected by different ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay results. ROF2181. Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Currently, only a few international institutions use CIRT to treat ...

8. 脑肿瘤项目- 临床试验- 妙佑医疗国际

   CfDNA Assay Prospective Observational Validation For Early Cancer Detection And Minimal Residual Disease (CAMPERR). Rochester, Minn. The purpose of this ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...